Research programme: BACE1 protein inhibitors - Vitae Pharmaceuticals/Boehringer Ingelheim

Drug Profile

Research programme: BACE1 protein inhibitors - Vitae Pharmaceuticals/Boehringer Ingelheim

Alternative Names: BACE1 inhibitors - Vitae; Beta secretase inhibitors - Vitae; BI 1147560; VTP 36951

Latest Information Update: 02 Aug 2015

Price : $50

At a glance

  • Originator Vitae Pharmaceuticals
  • Developer Boehringer Ingelheim; Vitae Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 27 Jul 2015 Vitae Pharmaceuticals and Boehringer Ingelheim to end collaboration and license agreement for BACE inhibitors
  • 01 Apr 2015 Boehringer Ingelheim plans a phase I trial for Alzheimer's disease
  • 01 Apr 2015 Preclinical development is underway in Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top